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Chronic obstructive airway diseases such as chronic obstructive pulmonary disease (COPD), asthma, 
rhinitis, and obstructive sleep apnea (OSA) are amongst the most common treatable and preventable 
chronic conditions with high morbidity burden and mortality risk. We aimed to explore the existence 
of multimorbidity clusters in patients with such diseases and to estimate their prevalence and impact 
on mortality. We conducted an observational retrospective study in the EpiChron Cohort (Aragon, 
Spain), selecting all patients with a diagnosis of allergic rhinitis, asthma, COPD, and/or OSA. The 
study population was stratified by age (i.e., 15–44, 45–64, and ≥ 65 years) and gender. We performed 
cluster analysis, including all chronic conditions recorded in primary care electronic health records and 
hospital discharge reports. More than 75% of the patients had multimorbidity (co‑existence of two or 
more chronic conditions). We identified associations of dermatologic diseases with musculoskeletal 
disorders and anxiety, cardiometabolic diseases with mental health problems, and substance use 
disorders with neurologic diseases and neoplasms, amongst others. The number and complexity of 
the multimorbidity clusters increased with age in both genders. The cluster with the highest likelihood 
of mortality was identified in men aged 45 to 64 years and included associations between substance 
use disorder, neurologic conditions, and cancer. Large‑scale epidemiological studies like ours could 
be useful when planning healthcare interventions targeting patients with chronic obstructive airway 
diseases and multimorbidity.
The World Health Organization (WHO) identifies cardiovascular and respiratory diseases, cancer, and diabetes 
as the four major groups of non-communicable diseases with the highest prevalence and associated mortality 
 risk1. Chronic respiratory conditions contribute significantly to health loss and are responsible for more than 
5% of years lived with disability in patients older than 50  years2. Chronic obstructive airway diseases affect 
hundreds of millions of people worldwide. Among them, 400 million people suffer from allergic rhinitis, 300 
million from asthma, 210 million have a chronic obstructive pulmonary disease (COPD), and more than 100 
million are affected by obstructive sleep apnea (OSA)3. Rhinitis and asthma stand out in the early stages of life, 
with asthma representing the most common chronic disease in  children1. On the contrary, it seems that COPD 
and OSA appear later in life and usually in combination with frailty and disability.
Initiatives like Integrated Care Pathways for Airway Diseases (AIRWAYS–ICPs) have developed multi-sec-
torial care pathways for chronic respiratory diseases in  Europe4. The complex relationships among chronic 
obstructive airway diseases have been studied in different ways, from an etiopathogenic and clinical perspec-
tive. Although COPD, asthma, rhinitis, and OSA have a different etiology, all these entities share two common 
pathophysiological characteristics that may partly determine their similar multimorbidity. On the one hand, 
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these are diseases that cause airflow limitation in the lower (COPD and asthma) and upper (rhinitis and OSA) 
respiratory tract; on the other hand, there is a chronic inflammation of the  airways5–8.
Another relevant issue is that most of the patients affected by chronic obstructive airway diseases present 
multimorbidity (i.e., more than one chronic disease)9. Multimorbidity is associated with a reduction of the 
potential benefits of respiratory rehabilitation, lower quality of life, and increased  mortality10–12. Few studies 
have addressed multimorbidity in patients with chronic respiratory diseases from an epidemiological and com-
prehensive  approach13. As far as we know, there are no studies aimed at identifying different profiles of patients 
based on their comorbidity and including the combination of the most prevalent chronic obstructive airway 
diseases. In this context, large-scale population-based studies using clinical information from electronic health 
records could represent an excellent opportunity to generate real-world evidence on the epidemiology of the 
multimorbidity of chronic obstructive airway diseases. Investigating the nature of the associations among comor-
bidities may allow us to create new hypotheses on common underlying pathophysiological mechanisms and to 
identify groups of patients potentially susceptible to different clinical management, facilitating the development 
of specific preventive and therapeutic  approaches9.
This study aimed to explore the existence of multimorbidity clusters in patients with COPD, OSA, asthma, 
and/or rhinitis using cluster analysis, to clinically describe the clusters obtained, and to analyze their impact 
on mortality.
Results
The study population was composed of 127,530 individuals 15 years of age and older with a diagnosis of at 
least one of the chronic obstructive airway diseases studied, representing 10.2% of the reference population in 
the EpiChron Cohort. The most frequent chronic obstructive airway disease in both sexes was allergic rhinitis, 
followed by asthma, COPD, and OSA (Table 1). Allergic rhinitis and asthma were more frequent in women 
than in men, while COPD and OSA were more common in men. Three in every four patients had at least one 
co-existing chronic condition, with an average of 3.7 diseases per patient. Women showed a higher morbidity 
burden compared with men.
We included a total of 96,059 patients with multimorbidity in the cluster analysis. Our analysis revealed the 
existence of systematic associations between chronic diseases. We identified up to twenty-three different mul-
timorbidity clusters in the patients analyzed (Figs. 1 and 2), 11 in women, and 13 in men. The most common 
chronic comorbidities were cardiometabolic diseases (i.e., dyslipidemia, hypertension, diabetes, and obesity), 
mental health disorders (i.e., depression, anxiety, and substance use), dermatological diseases (i.e., dermatitis 
and eczema, and psoriasis), cardiovascular diseases (i.e., ischaemic heart disease, cardiac arrhythmia, and heart 
failure), and diseases of the musculoskeletal system (i.e., osteoporosis, arthropathy, low back pain, and kyphosco-
liosis). The complete output of the cluster analysis is available as supplementary material. 
Multimorbidity clusters in women. We found that both the number and complexity of the multimorbid-
ity clusters increased with age.
In women aged 15–44, we identified three clusters. The derma-neurotic-musculoskeletal one was the most 
prevalent and included conditions like dermatitis and eczema, disease of hair, anxiety, and low back pain. 
The metabolic-behavior problems cluster included metabolic diseases (i.e., obesity, dyslipidemia, and diabe-
tes), hypertension, behavior problems, and schizophrenia, and had the highest mortality risk. We also found a 
peripheral vascular-neurological cluster that included varicose veins as the most prevalent disease, followed by 
peripheral neuropathy and other neurological disorders.
Table 1.  Demographical and clinical characteristics of patients with chronic obstructive airway diseases. s.d. 
standard deviation, COPD chronic obstructive pulmonary disease. a Versus urban residence. b Defined as the 
simultaneous presence of two or more chronic diseases from a list of 114 conditions, including each chronic 
obstructive airway disease separately.
Characteristics Total (N = 127,530) Men (N = 61,176) Women (N = 66,354) p value
Age interval (N, %)  < 0.001
15–44 years 54,920 (43.0) 25,952 (42.4) 28,968 (43.7)
45–64 years 33,743 (26.5) 14,552 (23.8) 19,191 (28.9)
 > 65 years 38,867 (30.5) 20,672 (33.8) 18,195 (27.4)
Rural  residencea (N, %) 44,831 (35.2) 22,548 (36.9) 22,283 (33.6)  < 0.001
Multimorbidityb (N, %) 97,759 (76.6) 44,842 (73.3) 52,917 (79.8)  < 0.001
Mean number of chronic diseases (s.d.) 3.7 (2.8) 3.6 (2.9) 3.8 (2.8)  < 0.001
Chronic obstructive airway diseases (N, %)
Allergic rhinitis 65,043 (51.0) 28,677 (46.9) 36,366 (54.8)  < 0.001
Asthma 43,098 (33.8) 16,411 (26.8) 26,687 (40.2)  < 0.001
COPD 28,214 (22.1) 19,725 (32.2) 8,489 (12.8)  < 0.001
Obstructive sleep apnea 1529 (1.2) 1145 (1.9) 384 (0.6)  < 0.001
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In women aged 45–64, four clusters were observed. The cardiometabolic-depressive cluster with conditions 
such as hypertension, obesity, dyslipidemia, varicose veins, and depression was the most prevalent and with the 
highest mortality risk associated. We also found a dyslipidemic-depressive cluster that included only dyslipi-
demia and depression, a derma-neurotic-hearing loss cluster with conditions such as dermatitis and eczema, 
anxiety, deafness, and irritable bowel syndrome, and an undefined peripheral vascular cluster, all of which were 
not associated with increased mortality risk.
In women aged 65 and older, we described five clusters. The dyslipidemic-depressive cluster with conditions 
like dyslipidemia, hypertension, degenerative joint disease, osteoporosis, and depression was the most prevalent. 
The hypertensive group included diseases like hypertension, degenerative joint disease, and varicose veins and 
was the second most prevalent cluster. The osteoporotic cluster included only osteoporosis and varicose veins and 
was the less prevalent group. The depressive-degenerative cluster that included depression, hypertension, degen-
erative joint disease, cataract, dementia, or chronic ulcer of the skin had an increased mortality risk associated. 
Finally, the cardiometabolic complex-degenerative cluster presented the highest mortality risk, and it included 21 
chronic conditions; the most common ones were congestive heart failure, hypertension, arrhythmia, and diabetes.
Multimorbidity clusters in men. In men aged 15–44, we identified four clusters. The derma-neurotic-
musculoskeletal was similar to the group in young women, being the most prevalent one. The metabolic-periph-
eral vascular group included conditions such as metabolic diseases, varicose veins, and cervical pain, and it was 
the second most frequent. We also found a neuropsychotic-endocrine cluster that included neurological and 
endocrine diseases, schizophrenia, personality and developmental disorders and had the highest mortality risk 
among young men. Finally, we found a visual deficit-behavior problems cluster that was the less prevalent group.
In men aged 45–64, five clusters were observed. The depressive-vascular-diabetic cluster, with conditions such 
as depression, varicose veins, diabetes, or ischemic heart disease, and the cardiometabolic cluster that included 
diseases like metabolic disorders, prostatic hypertrophy, ischemic heart disease, and arrhythmia, presented a 
similar mortality risk associated. We identified a neuro-substance use-cancer group that included diseases like 
substance use, neurological disorders, other respiratory disorders, high impact malignant neoplasms, or arrhyth-
mia, and had the lowest prevalence and highest mortality risk associated. We also found a dermatological cluster 
that was associated with visual deficit disorders and dyslipidemia. In both men and women, the dermatological 
cluster included sensory deficits for the population aged 45–64. Finally, we found a dyslipidemic cluster that 
included dyslipidemia and low back pain and presented a similar mortality risk to the derma-visual deficit cluster.
In men aged 65 and older, we identified and described five clusters. The sensory-degenerative cluster included 
conditions such as degenerative joint disease, cataract, and dermatitis. The hypertensive cluster integrated by 
hypertension and diabetes, the cardiometabolic cluster with conditions such as dyslipidemia, hypertension, 
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Figure 1.  Prevalence of multimorbidity clusters in the study population based on gender and age, and odds 
ratios of association with mortality. COPD chronic obstructive pulmonary disease, OSA obstructive sleep apnea.
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Figure 2.  Disease composition of the multimorbidity clusters identified in the study population based on 
sex and age, according to prevalence ((P); proportional to node size) and prevalence ratios (PRs, we used the 
lowest PR for each disease). Each cluster has a color, if a node (disease) has more than one color, that disease is 
included in other clusters.
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diabetes, and obesity, and the prostatic-cardiometabolic cluster, similar to the cardiometabolic one but including 
prostatic hypertrophy, all these three groups had similar mortality risk and prevalence. Finally, we also found a 
cardiovascular complex-degenerative group that had the highest mortality risk. The most frequent diseases in 
this cluster were arrhythmia, other respiratory disorders, congestive heart failure, and depression. It also included 
other chronic conditions like high impact malignant neoplasms, substance use, chronic ulcer of the skin, and 
malignant neoplasms of the lung.
We presented the complete output of the cluster analysis as supplementary material in which we included the 
complete disease analysis with their prevalence and prevalence ratios to compare the chronic conditions used 
to decide the composition of each cluster.
Discussion
This study shows that multimorbidity affects three in every four patients with chronic obstructive airway dis-
eases, revealing the existence of multimorbidity clusters in all age groups and both genders. Cardiovascular and 
metabolic diseases were amongst the most common conditions in many clusters. We identified associations of 
cardiometabolic diseases with mental health problems, dermatologic diseases with musculoskeletal disorders, 
and neurologic diseases with substance use disorders and neoplasms, amongst others. Epidemiological findings 
for each multimorbidity cluster, including prevalence and impact on mortality, could be a useful tool when plan-
ning healthcare interventions targeting patients with the most prevalent chronic obstructive airway diseases and 
multiple chronic conditions.
Our study revealed that multimorbidity is more common in patients with chronic obstructive airway diseases 
than in the general population and with a higher mean number of chronic diseases per  patient14. This finding 
highlights the importance of implementing person-centered approaches in this population in clinical practice. 
The co-existence of conditions from different specialties in the same cluster constitutes a challenging situation 
for both clinicians and  patients14. Interventions for the clinical management of populations with multimorbidity 
have focused primarily on other non-communicable chronic diseases than respiratory  disorders2, and the small 
number of randomized clinical trials in patients with multiple chronic conditions results in uncertainty for the 
effectiveness of such  interventions15. Disease clustering in the population with chronic obstructive airway diseases 
may provide valuable information for the development of educational activities on how to handle these patients.
Preventable cardiovascular risk factors such as hypertension, dyslipidemia, diabetes, and obesity were amongst 
the most common chronic conditions in various multimorbidity clusters, especially in the elderly. Metabolic 
syndrome is frequently associated with asthma, COPD, and OSA, but the nature of this relationship remains 
 unclear16. In patients aged 45 and older, we found that metabolic diseases were associated with cardiovascular 
conditions in both genders; expected cardiometabolic clusters where COPD and OSA were especially prevalent. 
Systematic associations between COPD, diabetes, hypertension, and cardiovascular diseases such as cardiac 
arrhythmia and ischemic heart disease have been identified in adults over 45 years  old17. These cardiovascular 
diseases share various common risk factors with COPD and OSA, like smoking and  inflammation5, 18. Previ-
ous studies reported that a multimorbidity cluster of cardiovascular conditions, obesity, and diabetes in COPD 
patients with mild respiratory symptoms is associated with chronic low-grade systemic  inflammation19, 20, and 
also poorer health  outcomes18. Our findings showed that cardiovascular and cardiometabolic clusters have, in 
general, a higher likelihood of mortality, when compared with control groups. More studies are needed on this 
aspect in patients with chronic obstructive airway diseases and cardiometabolic comorbidities, considering the 
age of onset of the diseases and the treatments used. A recent study in OSA patients demonstrated the reduction 
of some inflammatory biomarkers after long-term treatment with CPAP and/or surgery of the upper airway in 
moderate-to-severe OSA  patients5. Regarding COPD patients a large observational study reported that irrespec-
tive of history of exacerbations, new initiation of inhaled long-acting β2-agonists or antimuscarinic antagonists 
is associated with 1.5 times higher severe cardiovascular  risk21.
Depression frequently co-exists in patients with respiratory disorders such as asthma and  COPD22, 23; in 
our study, it was common comorbidity in clusters with cardiometabolic diseases. In women, depression was 
amongst the main conditions in two multimorbidity clusters, the dyslipidemic-depressive, and the depressive-
degenerative clusters. In the last one, we found that depression was associated with hypertension, congestive 
heart failure, and degenerative diseases, with significantly high mortality risk. A recent study in COPD patients 
reported that cardiovascular disease is more prevalent in men, but its impact on mortality is higher in women, 
and that although depression is more common in women, its impact on mortality is similar in both  genders23.
The MeDALL study found a strong association of asthma, allergic rhinitis, and eczema in children, suggesting 
the possible existence of an allergic cluster in the pediatric  population24. Another study reported the existence of 
an allergic pattern in children, while in the population 15–29 years of age, growth and developmental disorders 
were also associated with asthma and  dermatitis14. The same study found that in men 30–44 years old, this pat-
tern included psoriasis. In patients 15–44 years old, we identified a derma-neurotic-musculoskeletal cluster with 
a high prevalence of allergic rhinitis and asthma among the chronic obstructive airway diseases and associated 
with dermatitis. This cluster also included psoriasis, kyphoscoliosis, and congenital anomalies, in both genders. 
Another relevant comorbidity in this cluster was anxiety and neuroses, and sensory-processing disorders (hearing 
loss in women and visual impairment in men). Further studies are needed to research the relationship between 
these associations, especially in the case of sensory-processing disorders, congenital anomalies and some mus-
culoskeletal diseases in which there are very few studies reporting  them25, 26.
Substance use disorder was the leading condition of the multimorbidity cluster with the highest likelihood of 
mortality in our study (ten times higher compared with the control group). It was identified in men 45–64 years 
old and included associations between neurologic disorders, cardiovascular diseases, and cancer, amongst other 
conditions, and had the highest prevalence of COPD. An unexpected cluster but with a logical sense. It is well 
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established that tobacco is one of the main risk factors for COPD and lung  cancer27, 28. Also, it has been reported 
that inhalation of heroin and cocaine by asthmatic patients increases asthma exacerbations and decreases pul-
monary  function29. Besides the direct deleterious effect of some substances, potential interactions with drugs 
should also be considered, especially in patients with multiple chronic conditions.
A recent study revealed significant drug–drug interactions in patients with respiratory  diseases30; an example 
is the interaction of fentanyl with macrolides, which may increase the effect of the opioids. The importance of 
the present study is that it reveals unexpected systematic associations between chronic diseases, providing valu-
able information to generate hypotheses for potential physiological (including pharmacological) causal comor-
bidities. The presence of complex diseases in patients with multiple chronic conditions is challenging to assess, 
highlighting the importance of conducting further large-scale studies on the epidemiology of multimorbidity.
One of the principal strengths of our research is that it was conducted on a population-based cohort, includ-
ing 98% of the reference population. We exhaustively studied the morbidity burden in patients with the most 
common treatable and preventable chronic obstructive airway diseases by including all chronic diseases recorded 
in electronic health records in both primary and specialized healthcare settings to enhance external validity. 
Besides, the diagnosis of chronic obstructive airway diseases was based on reports of hospital admissions and 
discharges with radiological confirmation of the event. Data in the EpiChron Cohort undergo continuous qual-
ity control checkups that ensure its accuracy and reliability for research purposes. One of the core limitations is 
the cross-sectional retrospective nature of the study, which does not allow us to know temporal characteristics, 
such as the age of onset of the diseases. We also lack lifestyle information, socioeconomic factors, information on 
functional status, and analytical variables, among others. Another limitation of this study is that we had no access 
to the information on spirometries to confirm the disease diagnosis, which could be especially relevant in COPD 
patients. Nevertheless, COPD diagnosis is Spain is based on the GOLD  criteria31 and validated by the physicians 
in primary and hospital care. Furthermore, the use of spirometers in Aragon region has a penetration rate of 
80–100% in primary  care32, 33, with a higher proportion of trained healthcare professionals compared to other 
Spanish  regions32. However, the number of spirometries performed in primary care is relatively  low33, supporting 
the result that COPD patients in Spain have an estimated global under-diagnosis of 50–75%, which could impli-
cate that some younger and older patients with COPD were not included in our  study34, 35. This under-diagnosis 
could be the consequence of the interrelationship between primary care and hospital care, where preferably the 
spirometry is  performed33. Nonetheless, an over-diagnosis of COPD is also possible. A cross-sectional  study36 
conducted in 2017 in the primary care setting in Spain reported an over-diagnose of COPD of 21%. We had to 
acknowledge this potential over-diagnosis of COPD in our population as a limitation of the study, which would 
contribute to an over-diagnosis of chronic obstructive airway diseases of approximately 4%.
Conclusions
Multimorbidity affects almost three in every four patients with chronic obstructive airway diseases. The num-
ber and complexity of the identified multimorbidity clusters increase with age in both genders, revealing some 
unexpected systematic associations between diseases and a differential impact on mortality. The complex clinical 
profile of patients with the most prevalent chronic obstructive airway diseases highlights the need to implement 
holistic and person-centered clinical management approaches. Our findings may provide useful information 
when planning healthcare interventions targeting patients with chronic obstructive airway diseases and multiple 
chronic conditions. Further large-scale studies in different clinical settings and populations are encouraged to 
validate the results.
Methods
Study design and population. We conducted an observational retrospective study in the EpiChron 
Cohort. This cohort integrates, at the patient level, demographic and clinical information of the population 
assigned to the public health system in the Spanish region of Aragon (1.3 M individuals; approximately 98% of 
the total population of Aragon). The cohort profile, with a detailed description of data sources used, is published 
 elsewhere37.
The study population was composed of patients 15 years of age and older with a diagnosis of at least one of 
the following chronic obstructive airway diseases registered in patients’ primary care electronic health records 
and/or hospital discharge reports in 2011: allergic rhinitis, asthma, emphysema, chronic bronchitis, COPD, and/
or OSA. The identification of these entities was based on the diagnoses recorded in the clinical history of the 
patients and not on the pharmacological treatment received. This study was authorized by the Clinical Research 
Ethics Committee of Aragon (CEICA, PI16/0136). The CEICA did not require to obtain the patient’s informed 
consent since all the information used was anonymized. We performed this research in accordance with the 
Declaration of Helsinki, as revised in 2013, and the Spanish Law on the protection of personal data (LOPD 
15/1999 of December 14).
Measurements. For each patient, we analyzed the following variables: age as of December 31, 2011, sex, 
place of residence (urban/rural), all diagnoses of chronic diseases, multimorbidity (defined as the simultaneous 
presence of two or more chronic diseases), and all-cause mortality during 2012–2014. We stratified age into 
three age intervals (i.e., 15–44, 45–64, and ≥ 65 years).
Diagnoses were coded initially according to the International Classification of Primary Care or to the Inter-
national Classification of Diseases, in its Ninth Revision, Clinical Modification (ICD-9-CM), and subsequently 
grouped in Expanded Diagnostic Clusters (EDCs) according to the Johns Hopkins ACG System (version 11.0, 
Johns Hopkins University, Baltimore, MD, USA)38. We considered for the study the 114 chronic EDCs defined 
by Salisbury et al.39 as those diseases whose duration is ≥ 6 months, including the conditions of the past that 
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require continued care and those at risk of recurrence. We also included allergic rhinitis in the analysis, as it is 
considered a chronic disease by the  WHO3.
Statistical analysis. We reported the clinical and demographic characteristics of the population with 
chronic obstructive airway diseases as means and/or frequencies, and differences according to sex were analyzed 
using the Chi-square test and the Wilcoxon test.
We used cluster analysis in each age and gender group to identify clusters of similar individuals according to 
their comorbidities. This technique allows assigning cases (i.e., patients) to groups so that those from the same 
cluster resemble each other more than those from other clusters in terms of comorbidity. Only patients with 
multimorbidity and diseases with prevalence higher than 1% were included in the cluster analysis. For each 
patient, we included in the analysis dichotomous variables representing the presence/absence of each of the 
comorbidities studied. The grouping unit was the  individual40, with a total number of 97,759 patients included 
in the cluster analysis.
The selection of the cluster method followed an optimization process. First, we performed an agglomerative 
hierarchical method. However, this approach had computational limitations that required to perform the analysis 
in a sample of the population. For this reason, we finally decided to perform a k-means non-hierarchical analysis 
that allowed us to combine the statistical and clinical criteria for the selection of the number of clusters. We used 
the Jaccard coefficient as a measure of similarity because of the dichotomous nature of the diagnostic variables. 
This parameter establishes the distance between patients based on the number of observations (i.e., chronic 
conditions) they have in common and ignores the diagnoses that neither of them has. For the selection of the 
number of clusters, we aimed at maximizing model´s parsimony and we therefore looked for the lowest cluster 
number maximizing homogeneity within groups and heterogeneity between them and that had a consistent clini-
cal interpretation. In this decision, we also considered the Calinski and Harabasz statistic to help to determine 
the optimal statistical number of clusters to be extracted in each group, which is indicated by the highest value 
of this  statistic41, 42, however, this criterion was not always followed. The selection of the number of clusters and 
their clinical interpretation followed a process in which the clinical partners (J.C.-P., F.G.-R., I.I.-S., L.A.G.-M., 
J.D.-M., J.M.M., and A.P.-T.) were asked their opinion on the best option and discuss it in consecutive rounds if 
necessary. Thus, for each age and sex group, each clinical partner proposed the optimal number (and a second 
option if thought appropriated), and we valued all the opinions together until a consensus was reached.
We calculated the prevalence of each disease in each of the identified clusters. For each disease, we expressed 
prevalence differences among different clusters as prevalence ratios (PR). Prevalence and PR helped to define 
the disease composition of each cluster. A disease was initially included in a cluster if (1) the prevalence was 
higher than 25%, or (2) the PR was ≥ 2 in at least two-thirds of the comparisons with a prevalence higher than 
2%, or (3) the PR was ≥ 1.5 in all comparisons and the prevalence was higher than 2%. In the case of doubts, the 
decision was made based on the clinical interpretation of the cluster according to common pathophysiological 
mechanisms, clinical relevance, and prevalence. The denomination of the clusters was agreed according to the 
most relevant diseases within each pattern, considering their prevalence, prevalence ratio, and clinical relevance, 
and the denominations already used in the literature.
For each cluster, we performed an age-adjusted logistic regression analysis to determine if the mortality (%) 
was different between clusters taking as reference the group with chronic obstructive airway diseases and no 
multimorbidity. We conducted all the analyses in STATA software (Version 12.0, StataCorp LLC, College Station, 
TX, US), and statistical significance was established at p < 0.05.
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